Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729427 | 0.93 | KCNH2 (0.44) | MAPTSMN1; SMN2KCNH2MCHR1LMNA | |
| SCHEMBL22729785 | 0.80 | CHRM1 (0.51) | MAPTMCHR1LMNAKDM4E | |
| SCHEMBL22729461 | 0.79 | KCNH2 (0.41) | SPRKCNH2MCHR1TP53THRB | |
| SCHEMBL22729594 | 0.79 | SPR (0.38) | SPRKCNH2MCHR1LMNATP53 | |
| SCHEMBL29839340 | 0.77 | CACNB4 (0.45) | MAPTSPRLMNATP53GAA | |
| SCHEMBL22729645 | 0.77 | CACNB4 (0.45) | MAPTSPRLMNATP53GAA | |
| SCHEMBL22729604 | 0.74 | NTRK1 (0.43) | SPRKCNH2 | |
| SCHEMBL22729848 | 0.73 | PRKAA2 (0.44) | SPRKDM4E | |
| SCHEMBL22729466 | 0.72 | NPBWR1 (0.43) | MAPTMCHR1LMNATP53KDM4E | |
| SCHEMBL22729599 | 0.71 | MAPT (0.39) | MAPTSMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MAPT 356/4885SMN1; SMN2 151/4885SPR 4788/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | MAPT 364/4885SMN1; SMN2 155/4885SPR 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.